MeSH D054437 - myelodysplastic-myeloproliferative diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Imatinib | Imatinib Accord | 2013-06-30 | |||
| Allergan | Imatinib | Imatinib Actavis | 2013-04-17 | |||
| Amneal Pharmaceuticals | Imatinib | Imatinib | 2019-02-08 | |||
| Apotex | Imatinib | Imatinib | 2016-08-05 | |||
| Chartwell Pharmaceuticals | Imatinib | Imatinib | 2019-01-17 | |||
| CSPC Ouyi Pharmaceutical | Imatinib | Imatinib | 2025-04-21 | |||
| Dr Reddys Laboratories | Imatinib | Imatinib | 2018-08-13 | |||
| Eugia Pharma Specialties | Imatinib | Imatinib | 2020-07-23 | |||
| Hetero | Imatinib | Imatinib | 2025-04-14 | |||
| Hikma Pharmaceuticals | Imatinib | Imatinib | 2018-07-13 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
79%27/34
Phase 2
26%12/47
Phase 3
14%2/14
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use